HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

T Hirashima Selected Research

Leukopenia

10/2015A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
6/2013The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


T Hirashima Research Topics

Disease

8Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2019 - 06/2000
3Neoplasms (Cancer)
06/2013 - 05/2000
3Lung Neoplasms (Lung Cancer)
05/2013 - 09/2001
3Small Cell Lung Carcinoma (Small Cell Lung Cancer)
12/2011 - 07/2001
2Neutropenia
10/2015 - 06/2013
2Anemia
10/2015 - 06/2013
2Leukopenia
10/2015 - 06/2013
2Hyperthermia
01/2009 - 01/2008
2Brain Neoplasms (Brain Tumor)
01/2009 - 01/2008
2Body Weight (Weight, Body)
09/2002 - 01/2000
2Renal Insufficiency (Renal Failure)
12/2000 - 08/2000
1Colorectal Neoplasms (Colorectal Cancer)
01/2016
1Febrile Neutropenia
10/2015
1Nausea
11/2013
1Exanthema (Rash)
11/2013
1Anorexia
06/2013
1Fatigue
06/2013
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
05/2013
1Disease Progression
04/2013
1Interstitial Lung Diseases (Interstitial Lung Disease)
12/2011
1Neoplasm Metastasis (Metastasis)
01/2009
1Cicatrix (Scar)
08/2008
1Malignant Mesothelioma
08/2008
1Cerebrovascular Disorders (Cerebrovascular Occlusion)
12/2000
1Myocardial Ischemia (Ischemic Heart Diseases)
12/2000
1Insulin Resistance
01/2000
1Type 2 Diabetes Mellitus (MODY)
01/2000

Drug/Important Bio-Agent (IBA)

5ErbB Receptors (EGF Receptor)IBA
12/2019 - 03/2008
3Gefitinib (Iressa)FDA Link
12/2019 - 03/2008
3Tyrosine Kinase InhibitorsIBA
12/2019 - 11/2013
3ARQ 197IBA
10/2015 - 06/2013
3Erlotinib Hydrochloride (CP 358,774)FDA Link
10/2015 - 01/2009
3Carboplatin (JM8)FDA LinkGeneric
05/2013 - 07/2001
2Cytochrome P-450 CYP2C19IBA
11/2013 - 06/2013
2AgarIBA
01/2009 - 01/2008
2Triglycerides (Triacylglycerol)IBA
09/2002 - 01/2000
2Glucose (Dextrose)FDA LinkGeneric
09/2002 - 01/2000
2Telomerase (Telomerase Reverse Transcriptase)IBA
09/2001 - 05/2000
1Cisplatin (Platino)FDA LinkGeneric
12/2019
1Docetaxel (Taxotere)FDA Link
12/2019
1Bevacizumab (Avastin)FDA Link
01/2016
1Adenosine Triphosphate (ATP)IBA
11/2013
1Paclitaxel (Taxol)FDA LinkGeneric
05/2013
1Tyr sulfate(1)- enkephalinamide-Leu (LETS)IBA
05/2013
1Pemetrexed (MTA)FDA Link
04/2013
1Topotecan (Hycamtin)FDA LinkGeneric
12/2011
1CholesterolIBA
09/2002
1Blood Glucose (Blood Sugar)IBA
09/2002
1Etoposide (VP 16)FDA LinkGeneric
07/2001
1Messenger RNA (mRNA)IBA
06/2000
1Lipoprotein Lipase (Diacylglycerol Lipase)IBA
01/2000
1Insulin (Novolin)FDA Link
01/2000

Therapy/Procedure

3Drug Therapy (Chemotherapy)
05/2013 - 12/2011
3Therapeutics
04/2013 - 08/2000
1Surgical Instruments (Clip)
08/2008
1Length of Stay
12/2000